Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
6 hedge funds and large institutions have $416K invested in Cellular Biomedicine Group, Inc. in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
14% less funds holding
Funds holding: 7 → 6 (-1)
20% less capital invested
Capital invested by funds: $522K → $416K (-$106K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$261K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$126K |
| 2 |
Morgan Stanley
New York
|
-$47.9K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$11K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $219K | +$261K | +17,025 | New |
|
|
2
Goldman Sachs
New York
| $152K | -$126K | -8,252 | -41% |
|
3
UBS Group
Zurich,
Switzerland
| $34K | +$40.8K | +2,663 | New |
|
|
BIT
4
BlackRock Institutional Trust
San Francisco,
California
| $10K | – | – | – |
|
|
MFS
5
MSI Financial Services
Springfield,
Massachusetts
| $1K | – | – | – |
|
|
6
Morgan Stanley
New York
| – | -$47.9K | -3,131 | -99% |
|
|
7
Bank of America
Charlotte,
North Carolina
| – | -$11K | -502 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$4K | -170 | Closed |
|
CBMG Hedge Fund Activity: Q4 2014 in Review
6 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2014, worth a combined $416K — down 20% from $522K a quarter earlier.
Fund positioning in CBMG was balanced in Q4 2014: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $261K. The largest seller was Goldman Sachs, cutting an estimated $126K.
- 6 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2014, down from 7 in Q3 2014.
- Funds reported $416K of Cellular Biomedicine Group, Inc. stock for Q4 2014, down 20% quarter-over-quarter.
- 2 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2014 and 2 closed out, a net change of 0 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2014 was Geode Capital Management, an estimated $261K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2014 was Goldman Sachs, an estimated $126K sold.
Based on aggregated 13F filings for Q4 2014.